Baxalta now part of Shire
Trial Pipeline
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
NCT02932618
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
NCT01687608
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
NCT03879135
A Study of BAX 888 in Male Adults With Severe Hemophilia A
NCT03370172
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
NCT02955355
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
NCT02593188
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
NCT02283268
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
NCT01485796
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
NCT00782106
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
NCT00357656
ADVATE Post Authorization Safety Surveillance
NCT00214734
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 1 |
What the Pipeline for Baxalta now part of Shire Shows
According to the ClinicalTrials.gov registry, Baxalta now part of Shire is linked to 12 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 8% of the sponsor's indexed portfolio — and 9 are already marked complete, representing roughly 75% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Baxalta now part of Shire reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Baxalta now part of Shire is Hemophilia A with 4 linked trials, and 5 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.